Study of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid Leukemia
NCT ID: NCT04789408
Last Updated: 2025-07-11
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1
15 participants
INTERVENTIONAL
2021-07-19
2024-05-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT01253447
Study of XL999 in Patients With Acute Myeloid Leukemia (AML)
NCT00322673
CLL-1/CD33 Targeted LCAR-AMDR Cells in Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT05654779
Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML
NCT02091245
Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors
NCT05775406
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1: KITE-222 (Low Dose)
Participants with relapsed or refractory (r/r) acute myeloid leukemia (AML) will receive lymphodepleting chemotherapy (fludarabine and cyclophosphamide) followed by a single infusion of KITE-222 chimeric antigen receptor (CAR) transduced autologous T cells administered intravenously (IV) at a low dose on Day 0 based on participants body weight.
Cyclophosphamide
Administered intravenously
Fludarabine
Administered intravenously
KITE-222
A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously
Cohort 2: KITE-222 (Higher Dose)
Participants with r/r AML will receive lymphodepleting chemotherapy (fludarabine and cyclophosphamide) followed by a single infusion of KITE-222 CAR transduced autologous T cells administered IV at a higher dose on Day 0 based on participants body weight.
Cyclophosphamide
Administered intravenously
Fludarabine
Administered intravenously
KITE-222
A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously
Cohort 3: KITE-222 (Highest Dose)
Participants with r/r AML will receive lymphodepleting chemotherapy (fludarabine and cyclophosphamide) followed by a single infusion of KITE-222 CAR transduced autologous T cells administered IV at the highest dose on Day 0 based on participants body weight.
Cyclophosphamide
Administered intravenously
Fludarabine
Administered intravenously
KITE-222
A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously
Dose Expansion
Participants will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single dose \[at the maximum tolerated dose (MTD) determined\] of KITE-222.
Cyclophosphamide
Administered intravenously
Fludarabine
Administered intravenously
KITE-222
A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cyclophosphamide
Administered intravenously
Fludarabine
Administered intravenously
KITE-222
A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Morphological disease in the bone marrow and/or peripheral blood within 28 days before enrollment
* Prior exposure to the relevant agent class for individuals with AML characterized by a mutation targeted by an approved therapy
* Institutional criteria for allogeneic (allo) - stem cell transplant (SCT) fitness must be met: individuals must have an identified stem-cell donor readily available for potential allo-SCT after therapy with KITE-222
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
* Adequate hematologic status, defined as:
* Absolute neutrophil count (ANC) ≥ 1000/µL unless, in the opinion of the investigator, cytopenia is due to underlying leukemia
* Platelet count ≥ 50,000/µL unless, in the opinion of the investigator, thrombocytopenia is due to underlying leukemia
* Absolute lymphocyte count (ALC) ≥ 100/µL
* Adequate renal, hepatic, pulmonary and cardiac function defined as:
* Creatinine clearance (as estimated by the Cockcroft Gault formula) ≥ 60 mL/min
* Serum alanine aminotransferase/aspartate aminotransferase ≤ 2.5 x upper limit of normal
* Total bilirubin ≤ 1.5 mg/dL, except in individuals with Gilbert's syndrome
* Cardiac ejection fraction ≥ 50%, no clinically significant pericardial effusion as determined by an echocardiogram (ECHO), and no clinically significant electrocardiogram (ECG) findings
* Baseline oxygen saturation \> 92% on room air and no clinically significant pleural effusion as determined by chest imaging
* Contraception: males and females of childbearing potential must agree to use an effective method of contraception
* Pregnancy testing: females of childbearing potential must have a negative serum or urine pregnancy test
Exclusion Criteria
* Auto-SCT within the 6 weeks before enrollment
* Donor Lymphocyte Infusions (DLI) within 28 days prior to enrollment
* Any drug used for graft-versus-host-disease (GVHD) within 4 weeks prior to enrollment
* Acute GVHD grade II-IV by Mount Sinai Acute GVHD International Consortium criteria
* Active central nervous system (CNS) disease involvement
* Requirement for urgent therapy due to ongoing or impending oncologic emergency (eg, leukostasis or tumor lysis syndrome (TLS)) or the possible requirement for urgent therapy due to ongoing or impending oncologic emergency (eg, spinal cord compression, bowel obstruction, leukostasis, or TLS) at the time of enrollment or KITE-222 infusion
* History of C-type lectin-like molecule-1 (CLL-1)-directed therapy or genetically modified T-cell therapy
* History of malignancy other than nonmelanoma skin cancer or carcinoma in situ (eg, cervix, bladder, or breast) unless disease free for at least 3 years after the last definitive therapy
* History of severe hypersensitivity reaction to aminoglycosides
* History of concomitant genetic syndrome associated with bone marrow failure
* Individuals with a genetic syndrome that increases the risk of allo-SCT, including Down syndrome (trisomy 21)
* History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, New York Heart Association Class II or greater congestive heart failure, atrial fibrillation, or other clinically significant cardiac disease within 12 months before enrollment
* Individuals with cardiac atrial or ventricular leukemia involvement
* History of symptomatic deep vein thrombosis (DVT) or a pulmonary embolism within 6 months of enrollment. History of upper extremity line related DVT within the 3 months of conditioning chemotherapy.
* Primary immunodeficiency disorders
* History of a human immunodeficiency virus (HIV) infection or acute or chronic active hepatitis B or C infection
* History of an autoimmune disease resulting in end-organ injury or requiring systemic immunosuppression or systemic disease modifying agents within the last 2 years
* History or presence of a CNS disorder
* Presence or suspicion of a fungal, bacterial, viral, or other infection that is uncontrolled or requiring antimicrobials for management
* Live vaccine received within the ≤ 4 weeks before enrollment, or anticipation of the need for a live vaccination during the course of the study
* Inability to tolerate prophylactic antifungal and antibacterial therapy
* Presence of any indwelling line or drain
* Ongoing Grade 2 or higher toxicities from previous therapies, excluding hematologic toxicities
* Females of childbearing potential who are pregnant or breastfeeding
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kite, A Gilead Company
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kite Study Director
Role: STUDY_DIRECTOR
Kite, A Gilead Company
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Stanford Cancer Center
Stanford, California, United States
Moffitt Cancer Center
Tampa, Florida, United States
Washington University School of Medicine
St Louis, Missouri, United States
Cleveland Clinic
Cleveland, Ohio, United States
The Ohio State University Wexner Medical Center/James Cancer Hospital
Columbus, Ohio, United States
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Fred Hutchinson Cancer Center
Seattle, Washington, United States
Institut Paoli-Calmettes
Marseille, , France
CHU de Toulouse Institut Universitaire du Cancer Toulouse Oncopole
Toulouse, , France
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
Gilead Clinical Trials Website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020-000962-40
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
2023-507748-35
Identifier Type: OTHER
Identifier Source: secondary_id
KT-US-486-0201
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.